The FDA has approved Gilead’s combination drug Descovy for HIV prophylaxis in the US, offering a way of cutting the risk of sexually acquired infection with an improved safety profile compared ...
The government said in a pre-trial court filing it was entitled to up to $691 million in damages from Truvada and $311 million from Gilead's related drug Descovy. Gilead earned more than $1.8 ...
Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and Descovy for pre-exposure prophylaxis (PrEP). The government was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results